Automating Neurology Biologics Prior Auth for Faster Patient Access

Navigating the complexities of neurology biologics prior auth requires a specialized approach that accounts for intricate clinical criteria and frequent re-authorizations. Klivira automates this critical workflow, ensuring timely patient access to essential therapies.

Revenue cycle teams in neurology practices face significant administrative burdens managing prior authorizations for high-cost specialty biologics. The unique demands of conditions like Multiple Sclerosis, chronic migraine, and Alzheimer's disease necessitate precise documentation and adherence to evolving payer policies, often leading to delays and denials.

The Challenge of Neurology Biologics Prior Authorization

Neurology practices consistently manage high volumes of prior authorizations for biologics, particularly for disease-modifying therapies (DMTs) in Multiple Sclerosis, CGRP monoclonal antibodies for migraine prevention, and emerging anti-amyloid antibodies for Alzheimer's disease. These agents, while clinically transformative, are subject to stringent payer requirements that demand meticulous documentation and adherence to step therapy protocols.

Common Biologic Therapies Requiring Prior Auth in Neurology

MS disease-modifying therapies (e.g., ocrelizumab, natalizumab, oral DMTs)
Alzheimer's disease anti-amyloid antibodies (e.g., lecanemab, donanemab)
CGRP monoclonal antibodies for migraine prevention (e.g., erenumab, fremanezumab, galcanezumab, eptinezumab)
Spinal muscular atrophy and ALS treatments (e.g., nusinersen, risdiplam)
Botox for chronic migraine, spasticity, and dystonia
Select epilepsy specialty drugs (e.g., cenobamate, brivaracetam)

Navigating Complex Documentation and Step Therapy Requirements

Payer policies for neurology biologics often mandate specific clinical documentation, aligning with frameworks like AAN Practice Guidelines. This includes verifying MS diagnosis criteria, amyloid biomarker confirmation for Alzheimer's therapies, or documenting prior preventive therapy failures for CGRP migraine biologics. Non-compliance with step therapy requirements, such as trying moderate-efficacy DMTs before high-efficacy agents, is a frequent cause of initial denials.

Klivira's Targeted Automation for Neurology Biologics Prior Auth

**AAN-Guideline-Aware Logic:** Automating step-therapy adherence for MS DMTs and chronic migraine biologics.
**Alzheimer's Therapy Documentation:** Streamlining the capture of amyloid imaging or CSF biomarker confirmation and APOE genotyping.
**Dynamic Re-authorization Management:** Proactively managing periodic re-authorization cycles for chronic neurology treatments, including MRI monitoring requirements.
**EMR-Integrated Data Capture:** Leveraging FHIR data for indication classification, prior therapy history, and screening documentation (e.g., TB, hepatitis status).
**Payer Policy Integration:** Adapting to specific payer biosimilar substitution mandates and NCD/LCD constraints for advanced therapies.

Optimizing Workflows and Reducing Denials in Neurology

By automating the intricate requirements of neurology biologics prior authorization, Klivira significantly reduces the administrative burden on PA coordinators. This leads to fewer manual errors, expedited submission times, and a substantial decrease in initial denial rates, ultimately improving patient access to critical neurological therapies.

Frequently asked questions

How does Klivira handle step therapy for MS disease-modifying therapies (DMTs)?

Klivira utilizes AAN-guideline-aware logic to track prior DMT trials and ensure compliance with payer-specific step therapy protocols. This automation helps validate that required moderate-efficacy agents have been attempted before submitting prior authorizations for high-efficacy DMTs.

Can Klivira assist with prior authorization for Alzheimer's anti-amyloid antibodies?

Yes, Klivira automates the documentation process for anti-amyloid antibodies such as lecanemab. Our platform ensures that all required criteria, including amyloid confirmation (PET or CSF), MRI screening protocols, and APOE genotyping, are accurately captured and submitted for prior authorization.

What about re-authorization for chronic neurology biologic treatments?

Klivira proactively manages periodic re-authorization cycles for chronic neurology treatments. The platform prompts for updated disease activity and response documentation, including MRI monitoring requirements, ensuring continuous coverage and minimizing treatment interruptions.

How does Klivira integrate with our EMR for neurology prior authorization data?

Klivira leverages SMART on FHIR standards to integrate seamlessly with your EMR system. This allows for efficient extraction of relevant clinical data, such as diagnoses, prior therapy history, and screening results (e.g., TB, hepatitis status), directly into prior authorization requests, reducing manual data entry.

Does Klivira address CGRP migraine biologic prior authorizations?

Yes, Klivira tracks prior oral preventive trial failures and documents migraine days per month, aligning with payer step therapy and clinical criteria for CGRP monoclonal antibody approval. This streamlines the complex documentation often required for these preventive therapies.